Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

NCT01198522 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped lack of recruitment

Conditions

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection

Interventions

DRUG: L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine

Sponsor

Philogen S.p.A.